Aurisco Pharmaceutical Co Ltd
SSE:605116
Balance Sheet
Balance Sheet Decomposition
Aurisco Pharmaceutical Co Ltd
Current Assets | 1.3B |
Cash & Short-Term Investments | 521m |
Receivables | 269.5m |
Other Current Assets | 511.6m |
Non-Current Assets | 1.1B |
Long-Term Investments | 55.3m |
PP&E | 754.5m |
Intangibles | 120.6m |
Other Non-Current Assets | 134.1m |
Current Liabilities | 423m |
Accounts Payable | 124.6m |
Accrued Liabilities | 33.4m |
Short-Term Debt | 130.4m |
Other Current Liabilities | 134.5m |
Non-Current Liabilities | 74.9m |
Long-Term Debt | 38.3m |
Other Non-Current Liabilities | 36.6m |
Balance Sheet
Aurisco Pharmaceutical Co Ltd
Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
---|---|---|---|---|---|---|---|
Assets | |||||||
Cash & Cash Equivalents |
195
|
167
|
259
|
560
|
445
|
392
|
|
Cash |
0
|
0
|
0
|
0
|
440
|
340
|
|
Cash Equivalents |
195
|
167
|
259
|
560
|
4
|
52
|
|
Total Receivables |
141
|
142
|
157
|
170
|
160
|
241
|
|
Accounts Receivables |
127
|
121
|
134
|
143
|
141
|
221
|
|
Other Receivables |
15
|
21
|
23
|
27
|
19
|
20
|
|
Inventory |
188
|
228
|
240
|
238
|
327
|
445
|
|
Other Current Assets |
21
|
17
|
9
|
10
|
8
|
11
|
|
Total Current Assets |
546
|
554
|
665
|
978
|
940
|
1 088
|
|
PP&E Net |
229
|
328
|
383
|
507
|
717
|
742
|
|
PP&E Gross |
229
|
328
|
383
|
507
|
717
|
742
|
|
Accumulated Depreciation |
101
|
119
|
167
|
195
|
245
|
306
|
|
Intangible Assets |
33
|
33
|
43
|
42
|
40
|
123
|
|
Long-Term Investments |
0
|
0
|
0
|
0
|
15
|
55
|
|
Other Long-Term Assets |
8
|
6
|
10
|
6
|
9
|
24
|
|
Total Assets |
816
N/A
|
921
+13%
|
1 100
+19%
|
1 533
+39%
|
1 721
+12%
|
2 033
+18%
|
|
Liabilities | |||||||
Accounts Payable |
65
|
86
|
73
|
93
|
137
|
115
|
|
Accrued Liabilities |
20
|
18
|
19
|
23
|
41
|
42
|
|
Short-Term Debt |
22
|
9
|
6
|
4
|
0
|
65
|
|
Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
4
|
6
|
|
Other Current Liabilities |
22
|
17
|
19
|
21
|
10
|
94
|
|
Total Current Liabilities |
129
|
130
|
117
|
142
|
193
|
322
|
|
Long-Term Debt |
0
|
0
|
0
|
0
|
14
|
16
|
|
Deferred Income Tax |
1
|
1
|
2
|
2
|
2
|
2
|
|
Minority Interest |
0
|
0
|
0
|
0
|
2
|
8
|
|
Other Liabilities |
3
|
3
|
4
|
4
|
5
|
8
|
|
Total Liabilities |
132
N/A
|
133
+1%
|
123
-8%
|
148
+20%
|
215
+45%
|
357
+66%
|
|
Equity | |||||||
Common Stock |
360
|
360
|
360
|
401
|
401
|
406
|
|
Retained Earnings |
78
|
182
|
371
|
495
|
615
|
773
|
|
Additional Paid In Capital |
247
|
247
|
247
|
490
|
492
|
553
|
|
Treasury Stock |
0
|
0
|
0
|
0
|
0
|
57
|
|
Other Equity |
0
|
1
|
1
|
1
|
1
|
1
|
|
Total Equity |
684
N/A
|
788
+15%
|
977
+24%
|
1 385
+42%
|
1 506
+9%
|
1 676
+11%
|
|
Total Liabilities & Equity |
816
N/A
|
921
+13%
|
1 100
+19%
|
1 533
+39%
|
1 721
+12%
|
2 033
+18%
|
|
Shares Outstanding | |||||||
Common Shares Outstanding |
360
|
360
|
360
|
401
|
401
|
401
|